Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuemei Luo

Showing results (131-140 of 185) with videos related to

Pageof 19
Sort By:
Advances in Therapy|September 27, 2021
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic StatusAlexander T Cohen, Janvi Sah, Amol D Dhamane, et al.
Frontiers in Immunology|December 27, 2024
Targeting caspase-8: a new strategy for combating hepatocellular carcinomaHaoran Chen, Yumeng Lin, Jie Chen, et al.
Basic & Clinical Pharmacology & Toxicology|January 7, 2021
Prognostic value of liver and kidney function parameters and their correlation with the ratio of urine-to-plasma paraquat in patients with paraquat poisoningShuangyang Zhang, Shuai Song, Xuemei Luo, et al.
Journal of Thrombosis and Thrombolysis|May 2, 2024
Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claimsGregory Y H Lip, Virginia Noxon, Amiee Kang, et al.
Blood Advances|January 29, 2020
Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analysesDerek Weycker, Gail DeVecchis Wygant, Jennifer D Guo, et al.
Journal of Clinical Medicine|February 24, 2024
Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial FibrillationSteven Deitelzweig, Amiee Kang, Jenny Jiang, et al.
Journal of Proteome Research|July 7, 2017
Activation of Human Peripheral Blood Eosinophils by Cytokines in a Comparative Time-Course Proteomic/Phosphoproteomic StudyKizhake V Soman, Susan J Stafford, Konrad Pazdrak, et al.
Advances in Therapy|February 22, 2023
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for RecurrencesAlexander T Cohen, Janvi Sah, Amol D Dhamane, et al.
BMC Bioinformatics|July 29, 2006
PIPE: a protein-protein interaction prediction engine based on the re-occurring short polypeptide sequences between known interacting protein pairsSylvain Pitre, Frank Dehne, Albert Chan, et al.
Urology|October 6, 2015
Real-World Patterns of Care for the Overactive Bladder Syndrome in the United StatesHoward B Goldman, Jennifer T Anger, Canan B Esinduy, et al.
Pageof 19

Showing results (131-140 of 185) with videos related to

Sort By:
Pageof 19
Advances in Therapy|September 27, 2021
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic StatusAlexander T Cohen, Janvi Sah, Amol D Dhamane, et al.
Frontiers in Immunology|December 27, 2024
Targeting caspase-8: a new strategy for combating hepatocellular carcinomaHaoran Chen, Yumeng Lin, Jie Chen, et al.
Basic & Clinical Pharmacology & Toxicology|January 7, 2021
Prognostic value of liver and kidney function parameters and their correlation with the ratio of urine-to-plasma paraquat in patients with paraquat poisoningShuangyang Zhang, Shuai Song, Xuemei Luo, et al.
Journal of Thrombosis and Thrombolysis|May 2, 2024
Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claimsGregory Y H Lip, Virginia Noxon, Amiee Kang, et al.
Blood Advances|January 29, 2020
Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analysesDerek Weycker, Gail DeVecchis Wygant, Jennifer D Guo, et al.
Journal of Clinical Medicine|February 24, 2024
Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial FibrillationSteven Deitelzweig, Amiee Kang, Jenny Jiang, et al.
Journal of Proteome Research|July 7, 2017
Activation of Human Peripheral Blood Eosinophils by Cytokines in a Comparative Time-Course Proteomic/Phosphoproteomic StudyKizhake V Soman, Susan J Stafford, Konrad Pazdrak, et al.
Advances in Therapy|February 22, 2023
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for RecurrencesAlexander T Cohen, Janvi Sah, Amol D Dhamane, et al.
BMC Bioinformatics|July 29, 2006
PIPE: a protein-protein interaction prediction engine based on the re-occurring short polypeptide sequences between known interacting protein pairsSylvain Pitre, Frank Dehne, Albert Chan, et al.
Urology|October 6, 2015
Real-World Patterns of Care for the Overactive Bladder Syndrome in the United StatesHoward B Goldman, Jennifer T Anger, Canan B Esinduy, et al.
Pageof 19